| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.1M | +4.8% |
| R&D Expense | $655K | -17.3% |
| SG&A Expense | $2.6M | -1.1% |
| Operating Income | -$3.0M | +11.8% |
| Net Income | -$2.7M | +19.2% |
| EPS (Basic) | -$1.95 | -387.5% |
| EPS (Diluted) | -$1.95 | -387.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.5M | -50.4% |
| Short-term Investments | $340K | — |
| Accounts Receivable | $195K | +126.8% |
| Current Assets | $3.3M | -38.1% |
| Total Assets | $4.4M | -34.5% |
| Current Liabilities | $593K | -12.2% |
| Total Liabilities | $874K | +0.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$2.4M | -54.3% |
| Capital Expenditures | $20K | -31.8% |
| Investing Cash Flow | -$22K | +74.9% |
| Financing Cash Flow | -$118K | -102.0% |
| Free Cash Flow | -$2.4M | -52.7% |
| Stockholders' Equity |
| $3.5M |
| -39.8% |